Clinical effects of umbilical cord blood mononuclear cell transplantation on Parkinson's disease

doi:10.3877/cma.j.issn.2095-1221.2020.06.004

Abstract

Abstract:

Objective

To observe the clinical efficacy of human umbilical cord blood mononuclear cell transplantation treatment for Parkinson's disease by lateral atlanto-occipital space puncture.

Methods

Thirty-one Parkinson's disease patients from the Department of Neurology in Liaocheng People's Hospital were treated with human umbilical cord blood mononuclear cell transplantation by lateral atlanto-occipital space puncture. The Unified Parkinson's Disease Rating Scale (UPDRS) Ⅱ/Ⅲ, Non-Motor Symptoms Scale for Parkinson's Disease (NMSS) , and Pittsburgh sleep quality index (PSQI) were used for assessment of each patient before treatment and 1, 3, 6 and 12 months after treatment. Repeated measures analysis of variance was used to compare the scores of multiple time points before and after treatment and the Bonferroni test was used to compare the scores of each time in pairs.

Results

(1) Compared with that before treatment, the score of UPDRS-Ⅱ in month 3, 6, 12 after treatmentwere decreased [ (17.75±6.81) points vs (13.67±5.62) points, (12.54±4.39) points, (10.41±4.31) points]; the score of UPDRS-III in month 3, 6, 12 after treatment were also decreased [ (28.53±14.75) points vs (21.65±10.11) points, (19.37±9.26) points, (16.12±7.44) points], and the differences were statistically significant (P < 0.05) . (2) Compared with that before treatment, the score of NMSS in month 1, 3, 6, 12 after treatment were decreased [ (58.94±35.74) points vs (50.27±31.06) points, (41.38±28.25) points, (38.42±25.73) points, (36.15±24.56) points], and the differences were statistically significant (P < 0.05) . The score of PSOI also showed a same change trend. (3) Compared with that before treatment, the LED in month 6, 12 after treatment were decreased [ (629.57±205.33) mg/d vs (435.54±160.62) mg/d, (300.71±135.83) mg/d], and the differences were statistically significant (P < 0.05) .

Conclusions

Human umbilical cord blood mononuclear cell transplantation treatment for Parkinson's disease by lateral atlanto-occipital space puncture can improve the motor and non-motor symptoms and retard the progression of the disease.

Key words: Lateral atlanto-occipital space puncture, Humanumbilical cord blood mononuclear cell, Parkinson disease

Weifei Wang, Haiyan Yu, Xiaoling Yuan, Min Zhao, Min Wang, Qian Lu, Tian Wang, Dianrong Gong. Clinical effects of umbilical cord blood mononuclear cell transplantation on Parkinson's disease[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(06): 341-345.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2020.06.004

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2020/V10/I06/341

Figures/Tables 2

References 22

1	Gelders G, Baekelandt V, Van der Perren A. Linking neuroinflammation and neurodegeneration in Parkinson's disease[J]. J Immunol Res, 2018, 2018:4784268.
2	Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson's disease recognize α-synucleinpeptides[J]. Nature, 2017, 546(7660):656-661.
3	Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease[J]. Cell, 2016, 167(6):1469-1480.
4	Newcomb JD, Ajmo CT, Sanberg CD, et al. Timing of cord blood treatment after experimental stroke determines therapeutic efficacy[J]. Cell Transplant, 2006, 15(3):213-223.
5	Saporta S, Kim JJ, Willing AE, et a1. Human umbilical cord blood stem cells infusion in spinal cord injury: engraftment and beneficial influence on behavior[J]. J Hematother Stem Cell Res, 2003, 12(3):271-278.
6	宫殿荣, 于海燕, 赵敏, 等. 寰枕间隙侧方穿刺移植脐血单个核细胞治疗多系统萎缩的临床观察[J/CD]. 中华细胞与干细胞杂志(电子版), 2016, 6(2):115-120.
7	Gong D, Yu H, Yuan X. A new method of subarachnoid puncture for clinical diagnosis and treatment: lateral atlanto-occipital space puncture[J]. J Neurosurg, 2018, 129(1):146-152.
8	Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention[J]. Lancet Neurol, 2016, 15(12):1257-1272.
9	Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease—past insights and future potential[J]. Nat Rev Neurol, 2015, 11(9):492-503.
10	Wang YK, Zhu WW, Wu MH, et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson's disease[J]. Stem Cell Reports, 2018, 11(1):171-182.
11	Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease[J]. Transl Res, 2010, 155(2):62-70.
12	Yang WZ, Zhang Y, Wu F, et a1. Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions[J]. J Transl Med, 2010, 8:75.
13	Weiss ML, Troyer DL. Stem cells in the umbilical cord[J]. Stem Cell Rev, 2006, 2(2):155-162.
14	Zangiacomi V, Balon N, Maddens S, et a1. Human cord blood-derived hematopoietic and neural-like stern/progenitor cells are attracted by the neurotransmitter GABA[J]. Stem Cells Dev, 2009, 18(9):1369-1378.
15	Shetty P, Thakur AM, Viswanathan C. Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model[J]. Cell Biol Int, 2013, 37(2):167-80.
16	Karlupia N, Manley NC, Prasad K, et al. Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model[J]. Stem Cell Res Ther, 2014, 5(2):45.
17	Veizovic T, Beech JS, Stroemer RP, etal. Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells[J]. Stroke, 2001, 32(4):1012-1019.
18	Amer MH, Rose F, Shakesheff KM, et al. Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges[J]. NPJ Regen Med, 2017, 2:23.
19	Suzuki SO, Goldman JE. Multiple cell populations in the early postnatal subventricular zone take distinct migratory pathways: A dynamic study of glial and neuronal progenitor migration[J]. J Neurosci, 2003, 23(10):4240-4250.
20	Suzuki K, Miyamoto M, Miyamoto T, et al. Parkinson's disease and sleep/wake disturbances[J]. Curr Neurol Neurosci Rep, 2015,15(3):8.
21	Lee HJ, Lee JK, Lee H, et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation[J]. Neurobiol Aging, 2012, 33(3):588-602.
22	Pan K, Deng L, Chen P, et al. Safety and feasibility of repeated intrathecal allogeneic bone marrow-derived mesenchymal stromal cells in patients with neurological diseases[J]. Stem Cells Int, 2019, 2019: 8421281.

项目	例数	治疗前	治疗后				F值	P值
项目	例数	治疗前	1个月	3个月	6个月	12个月	F值	P值
UPDRS Ⅱ	31	17.75± 6.81	15.38± 6.14	13.67± 5.62	12.54±4.39	10.41±4.31	4.101	0.013
UPDRS Ⅲ	31	28.53±14.75	26.36±14.03	21.65±10.11	19.37±9.26	16.12±7.44	5.237	0.006

项目	例数	治疗前	治疗后				F值	P值
项目	例数	治疗前	1个月	3个月	6个月	12个月	F值	P值
UPDRS Ⅱ	31	17.75± 6.81	15.38± 6.14	13.67± 5.62	12.54±4.39	10.41±4.31	4.101	0.013
UPDRS Ⅲ	31	28.53±14.75	26.36±14.03	21.65±10.11	19.37±9.26	16.12±7.44	5.237	0.006

项目	例数	治疗前	治疗后				F值	P值
项目	例数	治疗前	1个月	3个月	6个月	12个月	F值	P值
NMSS（分）	31	58.94±35.74	50.27± 31.06	41.38± 28.25	38.42± 25.73	36.15± 24.56	6.375	0.000
PSOI（分）	31	11.68± 5.27	6.53± 4.92	3.68± 2.45	2.87± 1.63	2.14± 1.02	7.428	0.000
LED（mg/d）	31	629.57±205.33	593.35±194.82	551.36±190.14	435.54±160.62	300.71±135.83	4.061	0.015

项目	例数	治疗前	治疗后				F值	P值
项目	例数	治疗前	1个月	3个月	6个月	12个月	F值	P值
NMSS（分）	31	58.94±35.74	50.27± 31.06	41.38± 28.25	38.42± 25.73	36.15± 24.56	6.375	0.000
PSOI（分）	31	11.68± 5.27	6.53± 4.92	3.68± 2.45	2.87± 1.63	2.14± 1.02	7.428	0.000
LED（mg/d）	31	629.57±205.33	593.35±194.82	551.36±190.14	435.54±160.62	300.71±135.83	4.061	0.015

[1]	Chao Chen, Jing Duan, Aifang Shen, Wei Wang, Hao Song, Xianjie Lu, Xiaobing Wang, Zhongchao Han, Fabin Han. Effects of human umbilical cord blood mononuclear cells in a rat model of Parkinson's disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2017, 07(02): 71-76.
[2]	Yuanyuan Dang, Xiaoyu Xia, Yi Yang, Nan Liu, Tonghui Shan, Shaopeng Du, Zhiqiang Zhang, Jianghong He. Effect of asleep STN-DBS guided by image alone under general anesthesia in patients with Parkinson’s disease [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2020, 06(06): 350-355.
[3]	Xinyan Yi, Di Qiao, Xuan Zhang. Subthalamic nuclei-deep brain stimulation on motor symptoms in Parkinson′s disease [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2017, 07(02): 103-106.
[4]	Ruye Guo, Liming Meng, Nan Chen, Yuying Song, Haiyan Yin, Yan Guo. Research status on the neuroprotective efficacy and mechanism of Apelin/APJ system in Parkinson disease model [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 276-282.
[5]	Kaiyang Fan, Qiang Sun, Yu Zhang, Lili Lu, Jiaxin Song, Zhaojing Wang, Li Ma. Progress of proteomics in the diagnosis of Parkinson′s disease [J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(01): 63-65.

Please choose a citation manager

Content to export